Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.

MLA

Mickevicius, Tomas, et al. “Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.” Cornea, vol. 42, no. 4, Apr. 2023, pp. 507–19. EBSCOhost, https://doi.org/10.1097/ICO.0000000000003162.

APA

Mickevicius, T., Pink, A. E., Bhogal, M., O’Brart, D., & Robbie, S. J. (2023). Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management. Cornea, 42(4), 507–519. https://doi.org/10.1097/ICO.0000000000003162

Chicago

Mickevicius, Tomas, Andrew E Pink, Maninder Bhogal, David O’Brart, and Scott J Robbie. 2023. “Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.” Cornea 42 (4): 507–19. doi:10.1097/ICO.0000000000003162.